Cabio Biotech (Wuhan) Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	583.17	542.29	435.39	402.08	350.76	323.26
Other Revenue	13.31	13.31	8.41	31.35	0.35	0.21
Revenue	596.47	555.59	443.8	433.42	351.11	323.46
Revenue Growth (YoY)	17.85%	25.19%	2.40%	23.44%	8.55%	3.82%
Cost of Revenue	313.29	326.81	264.51	257.14	172.33	153.14
Gross Profit	283.19	228.78	179.29	176.29	178.78	170.32
Selling, General & Admin	75.22	72.35	56.34	64.32	42.18	35.75
Research & Development	44.53	47.57	38.23	31.84	30.54	20.18
Other Operating Expenses	14.18	5.36	6.38	4.56	5.01	4.6
Operating Expenses	131.33	125.82	103.21	111.93	77.08	60.56
Operating Income	151.85	102.97	76.08	64.35	101.7	109.76
Interest Expense	-1.24	-0.4	-0.6	-0.37	-0.35	-
Interest & Investment Income	6.04	3.52	7.41	7.12	16.83	20.84
Currency Exchange Gain (Loss)	2.78	2.78	1.08	11.28	-2.6	-6.37
Other Non Operating Income (Expenses)	0.88	-2.31	26.37	23.94	34.41	31.99
EBT Excluding Unusual Items	160.31	106.56	110.34	106.33	149.99	156.21
Gain (Loss) on Sale of Investments	-4.91	0.27	-2.64	-37.8	0.99	3.02
Gain (Loss) on Sale of Assets	-0	-0	0.05	0	-2.4	-1.31
Asset Writedown	-3.27	-5.21	-4.13	-0.69	-	-
Other Unusual Items	40.47	38.21	-3.62	10.29	3.48	-0.2
Pretax Income	192.6	139.82	100	78.14	152.06	157.73
Income Tax Expense	26.75	19.69	13.63	16.56	20.77	22.8
Earnings From Continuing Operations	165.85	120.13	86.37	61.58	131.29	134.94
Minority Interest in Earnings	3.82	4.08	5.01	2.79	-2.72	-4.35
Net Income	169.67	124.21	91.37	64.37	128.58	130.59
Net Income to Common	169.67	124.21	91.37	64.37	128.58	130.59
Net Income Growth	47.73%	35.94%	41.95%	-49.94%	-1.54%	10.50%
Shares Outstanding (Basic)	168	168	169	169	168	168
Shares Outstanding (Diluted)	168	168	169	169	168	168
Shares Change (YoY)	-0.70%	-0.80%	-0.11%	0.69%	0.31%	32.80%
EPS (Basic)	1.01	0.74	0.54	0.38	0.76	0.78
EPS (Diluted)	1.01	0.74	0.54	0.38	0.76	0.78
EPS Growth	48.77%	37.04%	42.10%	-50.28%	-1.84%	-16.79%
Free Cash Flow	61.11	-38.55	-228.79	-73.07	-70.14	112.78
Free Cash Flow Per Share	0.36	-0.23	-1.35	-0.43	-0.42	0.67
Dividend Per Share	0.201	0.201	0.200	0.214	0.236	0.236
Dividend Growth	0.47%	0.47%	-6.67%	-9.08%	-	-34.00%
Gross Margin	47.48%	41.18%	40.40%	40.67%	50.92%	52.66%
Operating Margin	25.46%	18.53%	17.14%	14.85%	28.97%	33.93%
Profit Margin	28.44%	22.36%	20.59%	14.85%	36.62%	40.37%
Free Cash Flow Margin	10.24%	-6.94%	-51.55%	-16.86%	-19.98%	34.87%
EBITDA	211.5	157.22	123.14	90.4	125.02	135.78
EBITDA Margin	35.46%	28.30%	27.74%	20.86%	35.61%	41.98%
D&A For EBITDA	59.65	54.25	47.06	26.04	23.32	26.01
EBIT	151.85	102.97	76.08	64.35	101.7	109.76
EBIT Margin	25.46%	18.53%	17.14%	14.85%	28.97%	33.93%
Effective Tax Rate	13.89%	14.08%	13.63%	21.19%	13.66%	14.45%
Revenue as Reported	596.47	555.59	443.8	433.42	351.11	323.46
Advertising Expenses	-	6.61	5.28	2.27	1.11	0.88

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.